LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated ("Cytokinetics†or the "Company†) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALL. ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025. Cytokinetics describes itself as a "biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in- class muscle inhibitors as potential treatments for debilitating diseases in which muscl. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

Core Points - Cytokinetics has announced the eighth annual Communications Grant Program aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure [2][3] - The program will award five grants to enhance communications, awareness, and community engagement within these patient communities [2][3] - The deadline for applications is November 3, 2025, with grant recipients to be announced in January 2026 [4] Group 1: Grant Program Details - The Communications Grant Program addresses a persistent funding gap in communications for patient advocacy organizations, which can hinder patient access to vital resources [3] - Grants may support programming or personnel, depending on the specific needs of the organizations [3] - Eligible organizations must be nonprofit or registered charities in the U.S., Canada, Europe, or the U.K., and serve HCM or heart failure patient communities [4] Group 2: Impact and Evaluation - Applications will be evaluated based on alignment with selection criteria, and recipients must provide an outcomes report to measure the impact of the funding [4] - The 2025 grant recipients include AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, Hypertrophic Cardiomyopathy Association, and Stichting Cardiomyopathie Onderzoek Nederland [3] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and is advancing a pipeline of potential new medicines for cardiac muscle dysfunction [5] - The company is preparing for potential regulatory approvals for aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [5] - Other investigational medicines in development include omecamtiv mecarbil, ulacamten, and CK-089, targeting various heart failure and muscular dystrophy conditions [5]

Core Insights - Cytokinetics is scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 [1] - The company is advancing a pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten, a cardiac myosin inhibitor, which is nearing regulatory approvals following positive Phase 3 trial results [3] - Cytokinetics is also developing other treatments such as omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy [3] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [3] - The company focuses on innovative treatments for patients suffering from diseases related to cardiac muscle dysfunction [3] - Aficamten is currently being evaluated in additional clinical trials for both obstructive and non-obstructive hypertrophic cardiomyopathy [3]

Group 1 - The article highlights the upcoming deadline of November 17, 2025, for investors to file a lead plaintiff motion in a case related to Cytokinetics, Incorporated [1] - The case is on behalf of investors who purchased Cytokinetics common stock during the class period from December 27, 2023, to May 6, 2025 [1] - Investors who suffered losses in Cytokinetics are encouraged to contact the Law Offices of Howard G. Smith for assistance [1]

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025, which is in violation of federal securities laws [3]. Group 1: Lawsuit Details - Investors have until November 17, 2025, to file lead plaintiff applications in the lawsuit against Cytokinetics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923 [5]. Group 2: Company Disclosures - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting to review its New Drug Application for the aficamten product [4]. - On May 6, 2025, the company revealed it had held multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy [4]. Group 3: Impact on Stock Price - Following the disclosures, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5]. Group 4: Law Firm Background - Kahn Swick & Foti, LLC is a prominent boutique securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including public and private institutional investors, in seeking recoveries for investment losses due to corporate fraud [5].

Core Viewpoint - Cytokinetics is facing a class action securities lawsuit due to alleged securities fraud related to the New Drug Application (NDA) for aficamten, which misled investors about the regulatory timeline and approval process [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by false statements regarding the NDA submission and approval timeline for aficamten between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly misrepresented the expected FDA approval timeline for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS) [2]. - The revelation during a May 6, 2025 earnings call indicated that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, leading to significant losses for investors when the truth was disclosed [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and being recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging investors of Cytokinetics, Incorporated (CYTK) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking investors who may have been affected by alleged securities fraud related to Cytokinetics [1] - The announcement indicates a growing concern among investors regarding the company's practices and potential legal implications [1]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Incorporated and certain of its officers, indicating potential legal challenges for the company [1] Group 1 - The lawsuit is being handled by Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, which may suggest the seriousness of the allegations [1] - The company is listed on NASDAQ under the ticker symbol CYTK, highlighting its status as a publicly traded entity [1]